Viswabhaskar Susarla

Dr. Viswabhaskar Susarla

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMargaret Gopaul
Margaret Gopaul
ACAnil Chimakurthy
Anil Chimakurthy
VSViswabhaskar Susarla
Viswabhaskar Susarla
AKAndres Kanner
Andres Kanner
Epilepsy prevalence sharply increases after age 65 years, but elderly adults are chronically underrepresented in key trials that form the licensing evidence base for antiseizure medications (ASMs), leaving clinicians to extrapolate from the experiences of younger cohorts. This narrative review aims to consolidate real-world evidence regarding the efficacy, safety, and tolerability of 4 commonly prescribed newer ASMs, perampanel (PER), lacosamide (LCM), eslicarbazepine acetate (ESL), and brivaracetam (BRV) among adults ≥65 years, provide pragmatic prescribing recommendations based on this evidence, and define key gaps where further study should be prioritized. Collating data from our structured search of observational cohorts, interventional trials and extensions, pooled and post hoc analyses, pharmacovigilance databases, and case series and reports, we found that reported effectiveness outcomes in older adults were generally comparable to those observed in broader adult populations, although heterogeneity across studies limits direct comparisons. ESL monotherapy produced 1-year retention rates of 72.7% and 6- and 12-month seizure freedom rates of 72.2% and 67.3% among patients ≥65 years; adjunctive LCM demonstrated superior seizure freedom rates among older versus younger patients (56.7% vs. 43.1%); and dedicated ≥65-year-old studies of ESL and BRV reaffirmed efficacy observed in overall populations, frequently at lower doses and slower titration schedules. Key safety signals were drug-specific: hyponatremia (more common and symptomatic in older adults) for ESL; dose-dependent PR interval prolongation and rare high-grade atrioventricular block/ventricular tachycardia, Brugada morphology, and sinus node dysfunction for LCM; and psychiatric or behavioral events, dose-dependent falls for PER. Evidence supported a class-wide relationship between chronic ASM exposure and falls and fractures, while a FAERS analysis found no significant drug reaction with eosinophilia and systemic symptoms (DRESS) signal for BRV and analysis-dependent findings for LCM. In conclusion, newer ASMs are efficacious and generally well tolerated among older adults. However, optimized safe prescribing in this population requires ASM selection tailored to comorbidities, lower starting doses with slower titration, and drug-specific follow-up (e.g., serum sodium monitoring for ESL, cardiac conduction assessment for LCM, and behavior and fall risk assessment for PER). Evidence remains lacking in adults ≥65 years of age, particularly for brivaracetam.

28 August 2026 in BMC Neurology
Verified
Journal Article
Open access
PDF file
ACAnil Chimakurthy
Anil Chimakurthy
VSViswabhaskar Susarla
Viswabhaskar Susarla
JCJeet Hemantkumar Chaudhary
Jeet Hemantkumar Chaudhary
ODOm Desai
Om Desai
Seizures after acquired brain injury pose distinct therapeutic questions: early seizure prophylaxis, treatment of acute symptomatic seizures, and late epil

22 August 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
VSViswabhaskar Susarla
Viswabhaskar Susarla
MGMariah George
Mariah George
ARAnanthi Rathinam
Ananthi Rathinam
DBDanish Bhatti
Danish Bhatti
Background: Brain MRI in patients with autism spectrum disorder (ASD) is generally considered when additional neurologic, developmental, or syndromic concerns warrant structural evaluation. In the study practice, ASD alone was not used as the reason to obtain MRI. We examined documented MRI use and broad result coding while explicitly separating selection for imaging from abnormal-result status. Methods: This retrospective specialty-practice cohort included 1884 patients with ASD. The primary outcome was the proportion of documented MRI examinations coded abnormal. Secondary analyses examined associations of age, sex, seizure history, EEG status, and genetic test status with abnormal versus normal MRI coding and with documented MRI utilization. MRI categories and the pediatric restriction were exploratory and sensitivity analyses. Results: An MRI result was recorded for 704 patients (37.4%; 95% CI 35.2–39.6); 322 were coded abnormal (45.7%; 95% CI 42.0–49.5). The abnormal-result models had low in-sample discrimination (AUC 0.528 and 0.553), and adjusted confidence intervals for all measured variables included 1.00; these results do not demonstrate equivalence between clinical groups. Seizure history was associated with documented imaging in the full cohort (aOR 2.47, 95% CI 1.94–3.14), and abnormal EEG was associated in the exploratory complete-case utilization model (aOR 2.83, 95% CI 1.93–4.14). Conclusions: Broad MRI abnormalities were frequent among patients selected for imaging because of additional clinical concerns, but a broad abnormal code is not equivalent to clinically actionable yield. The routinely captured variables available in this dataset were insufficient to distinguish abnormal from normal MRI coding. These findings favor individualized MRI decisions based on the clinical question prompting imaging and motivate future studies with richer neurologic and developmental phenotyping.

12 September 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
VSViswabhaskar Susarla
Viswabhaskar Susarla
MGMariah George
Mariah George
ARAnanthi Rathinam
Ananthi Rathinam
DBDanish Bhatti
Danish Bhatti
Background: Genetic testing in autism spectrum disorder (ASD) can reveal a wide range of chromosomal and sequence-level abnormalities, yet large real-world neurology cohorts rarely report the full spectrum of findings alongside clinical correlates and patterns of testing. We characterized genetic findings in an 1884-patient ASD cohort and examined factors associated with both abnormal findings and the use of genetic testing. Methods: This retrospective cross-sectional study included 1884 patients. Genetic testing was performed in 1011 patients; the primary outcome was an abnormal versus normal genetic result among those tested. All 371 abnormal findings were catalogued in a de-identified supplement. The primary multivariable model included age, sex, seizure history, and EEG abnormality (N = 901); an MRI-inclusive sensitivity model used 422 complete cases, and a separate full-cohort model evaluated factors associated with genetic testing. Results: Abnormal genetic findings were documented in 371/1011 tested patients (36.7%, 95% CI 33.7–39.8%). In the primary model, female sex (aOR 1.483, 95% CI 1.089–2.018; p = 0.012) and seizure history (aOR 1.634, 95% CI 1.136–2.352; p = 0.008) were independently associated with abnormal findings, whereas EEG abnormality was not significant after adjustment (aOR 1.373, p = 0.084). In the MRI-inclusive sensitivity model, female sex and seizure history remained significant, while MRI abnormality was not independently associated (aOR 1.235, p = 0.302). Genetic testing was more common among patients who also underwent EEG or MRI (both p < 0.001). Conclusions: More than one-third of tested patients had an abnormal genetic finding, spanning a broad range of copy-number, sequence, homozygosity, Fragile X-related, chromosomal, and syndromic findings. Seizure history and female sex were the principal adjusted correlates of abnormal findings. Genetic testing clustered with EEG and MRI use, reflecting observed patterns of neurological work-up within this cohort rather than temporal or causal relationships.